TASE

Gilat Completes Acquisition of DataPath, Inc.

Retrieved on: 
Thursday, November 16, 2023

“This acquisition is a strong step ahead in Gilat’s strategy to increase its presence in the growing defense market,” said Adi Sfadia, Gilat’s CEO.

Key Points: 
  • “This acquisition is a strong step ahead in Gilat’s strategy to increase its presence in the growing defense market,” said Adi Sfadia, Gilat’s CEO.
  • “DataPath, now as part of Gilat, will continue to offer superior solutions, not just within the U.S. DoD market, but throughout the world.
  • This acquisition’s synergies enhance Gilat’s and DataPath’s ability to develop solutions for the rapidly evolving satellite communication market.
  • As the SATCOM market enters a new space age, our combined resources and technologies further enhance Gilat’s strategy in the global defense sector.”
    Needham & Company LLC and Quilty Analytics LLC are serving as financial advisors to Gilat.

Alarum: NetNut Announces Grant of a United States Patent

Retrieved on: 
Wednesday, November 15, 2023

TEL AVIV, Israel, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of internet access and web data collection solutions, has announced that its wholly owned subsidiary, NetNut Ltd. (“NetNut”), was granted United States Patent No.

Key Points: 
  • TEL AVIV, Israel, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of internet access and web data collection solutions, has announced that its wholly owned subsidiary, NetNut Ltd. (“NetNut”), was granted United States Patent No.
  • This patent, officially granted on November 14, 2023, signifies a significant milestone in the Company’s commitment to advancing technology and delivering cutting-edge solutions to its customers.
  • The newly granted patent describes a revolutionary method, which brings a novel twist to traditional proxy services.
  • NetNut is committed to fostering innovation, and this patent represents a significant investment in our research and development initiatives.

BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 15, 2023

BURLINGTON, Mass. and JERUSALEM, Nov. 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported third quarter 2023 financial results and provided an operational update.

Key Points: 
  • and JERUSALEM, Nov. 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported third quarter 2023 financial results and provided an operational update.
  • For the three months ended September 30, 2023, revenues were $8.3 million, a 61% increase as compared to the third quarter of 2022 and a 6% increase as compared to the second quarter of 2023.
  • Gross margin for the third quarter of 2023 was 74%, steady from the same period in 2022, and an increase from 73% in the second quarter of 2023.
  • Operating loss for the third quarter of 2023 was $0.1 million, compared to a loss of $4.9 million for the same period in 2022 and $1.3 million for the second quarter of 2023.

Alarum to Release Third Quarter Results on November 28, 2023

Retrieved on: 
Tuesday, November 14, 2023

Tel Aviv, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of internet access and web data collection solutions, will release its financial results for the third quarter ended September 30, 2023, before the Nasdaq market opens on Tuesday, November 28, 2023.

Key Points: 
  • The Company Will Host a Conference Call on Tuesday, November 28, 2023, at 8:00 a.m. Eastern Time
    Tel Aviv, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of internet access and web data collection solutions, will release its financial results for the third quarter ended September 30, 2023, before the Nasdaq market opens on Tuesday, November 28, 2023.
  • Mr. Shachar Daniel, Chief Executive Officer of the Company, and Mr. Shai Avnit, Chief Financial Officer of the Company, will host a conference call on November 28, 2023, at 8:00 a.m. Eastern time, to discuss the financial results, followed by a Q&A session.
  • To attend the conference call, please dial one of the following teleconferencing numbers.
  • If you are unable to connect using the toll-free number, please try the international dial-in number:

Allot to Release Third Quarter 2023 Earnings on November 16, 2023 and Reschedules Conference Call to November 22, 2023

Retrieved on: 
Tuesday, November 14, 2023

This change has been necessitated by the diagnosis of COVID-19 for Mr. Erez Antebi, Allot’s Chief Executive Officer.

Key Points: 
  • This change has been necessitated by the diagnosis of COVID-19 for Mr. Erez Antebi, Allot’s Chief Executive Officer.
  • The unaudited financial results of the quarter will continue to be published before the market opens on Thursday, November 16, 2023.
  • To access the conference call on Wednesday, November 22, 2023, at 8:30 am ET, 3:30 pm Israel time, please dial one of the following numbers:
    A live webcast of the conference call can be accessed on the Allot website at http://investors.allot.com/ .
  • The webcast will also be archived on the website following the conference call.

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

Retrieved on: 
Monday, November 13, 2023

NEW YORK and TEL AVIV, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs.

Key Points: 
  • NEW YORK and TEL AVIV, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs.
  • "We are delighted to partner with Teva, to realize the potential of olanzapine LAI and support them as their innovative pipeline continues to come to fruition,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma.
  • “We are excited to collaborate with Royalty Pharma, a leading funder of innovation with a strong track record, experience, and reputation.
  • This funding agreement enables us to continue to accelerate the development of olanzapine LAI (TEV-‘749), a critical program for us, without impacting resources dedicated to our innovative and generic medicines.”
    Under the agreement, Royalty Pharma will provide Teva up to $100 million to fund ongoing development costs for olanzapine LAI (TEV-‘749), and Royalty Pharma and Teva have a mutual option to increase the total funding amount to $125 million.

Tower Semiconductor Reports 2023 Third Quarter Financial Results

Retrieved on: 
Monday, November 13, 2023

MIGDAL HAEMEK, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the third quarter ended September 30, 2023.

Key Points: 
  • MIGDAL HAEMEK, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the third quarter ended September 30, 2023.
  • Third quarter 2023 revenue of $358 million, as compared to $357 million for the second quarter of 2023.
  • Thank you to all our employees worldwide.”
    Revenue for the third quarter of 2023 was $358 million as compared with $357 million for the second quarter of 2023.
  • Gross profit for the third quarter of 2023 was $87 million as compared with $87 million for the second quarter of 2023.

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Monday, November 13, 2023

“Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.

Key Points: 
  • “Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.
  • Financial Highlights for the Three Months Ended September 30, 2023
    Total revenues were $37.9 million in the third quarter of 2023, an 18% increase from the $32.2 million recorded in the third quarter of 2022.
  • S&M costs, for the third quarter of 2023 and 2022, included $0.4 million of depreciation expenses of intangible assets generated through the IgG products acquisition.
  • Kamada continues to expect to generate fiscal year 2023 total revenues in the range of $138 million to $146 million.

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Retrieved on: 
Monday, December 18, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has submitted an Investigational New Drug amendment (INDa) to the U.S. Food and Drug Administration (FDA), for OPC1 , its investigational allogeneic oligodendrocyte progenitor cell transplant, for the treatment of spinal cord injury (SCI).

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has submitted an Investigational New Drug amendment (INDa) to the U.S. Food and Drug Administration (FDA), for OPC1 , its investigational allogeneic oligodendrocyte progenitor cell transplant, for the treatment of spinal cord injury (SCI).
  • Receipt of FDA clearance of the INDa would enable the Company to initiate its DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study, to evaluate the safety and utility of a novel spinal cord delivery device in both subacute and chronic SCI patients.
  • “The submission of our IND amendment for OPC1 and its return to clinical testing represents a significant milestone for this program and a diligent effort by our team,” stated Brian M. Culley, Lineage CEO.
  • We are encouraged by the meaningful quality of life and safety results observed with OPC1 in previous trials, and we look forward to building on that promising work.

Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

Retrieved on: 
Monday, December 18, 2023

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received a positive response from the U.S. Food and Drug Administration (FDA) on the Pediatric Study Plan for the treatment of children suffering from psoriasis with Piclidenoson.

Key Points: 
  • (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received a positive response from the U.S. Food and Drug Administration (FDA) on the Pediatric Study Plan for the treatment of children suffering from psoriasis with Piclidenoson.
  • The plan has been submitted to allow enrollment of children with psoriasis to Can-Fite’s upcoming Phase 3 pivotal clinical psoriasis studies, aiming at registration of Piclidenoson with both the FDA and the European Medicines Agency (EMA) for the treatment of plaque psoriasis.
  • There is a high market need for a safe and efficacious drug for the treatment of children who suffer from psoriasis.
  • Psoriasis affects millions of people worldwide, including a significant number of children who endure the physical and emotional burden of this challenging disease.